ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Malignant Mesothelioma Therapeutic Market Research Report 2025
Published Date: June 2025
|
Report Code: QYRE-Auto-13B13087
Home | Market Reports | Health| Health Conditions| Cancer
Global Malignant Mesothelioma Therapeutic Market Research Report 2023
BUY CHAPTERS

Global Malignant Mesothelioma Therapeutic Market Research Report 2025

Code: QYRE-Auto-13B13087
Report
June 2025
Pages:100
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Eli Lilly
TEVA
Sanofi
Bristol–Myers Squibb
Pfizer Inc
Roche
Merck
Ono Pharmaceutical
Mylan NV
Fresenius Kabi
Sun Pharmaceuticals
Eagle Pharmaceuticals
Qilu Pharma
Sichuan Huiyu Pharma
Nippon Kayaku
Amgen Inc
Jiangsu Haosen

The global market for Malignant Mesothelioma Therapeutic was valued at US$ 377 million in the year 2024 and is projected to reach a revised size of US$ 602 million by 2031, growing at a CAGR of 7.0% during the forecast period.

Malignant Mesothelioma Therapeutic Market

Malignant Mesothelioma Therapeutic Market

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium). Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.
The malignant mesothelioma therapeutics market is primarily driven by increasing asbestos exposure cases in developing nations and rising disease awareness among occupational workers. Significant advancements in immunotherapy and targeted therapies, particularly immune checkpoint inhibitors and VEGF inhibitors, are revolutionizing treatment outcomes. The FDA's accelerated approval pathway for orphan drugs and growing R&D investments in rare cancer treatments are further propelling market growth. Additionally, improved diagnostic techniques enabling earlier detection and a surge in biomarker-driven personalized medicine approaches are creating new therapeutic opportunities.
The market faces substantial hurdles including late-stage diagnosis in most patients, severely limiting treatment efficacy. High development costs for novel therapies and limited patient pools due to mesothelioma's rarity create commercial viability concerns for pharmaceutical companies. Stringent asbestos regulations in developed countries are reducing incident rates, paradoxically shrinking the addressable market. Furthermore, the lack of standardized treatment protocols and frequent chemotherapy resistance present significant clinical management challenges, while reimbursement issues for expensive emerging therapies restrict patient access in many healthcare systems.
This report aims to provide a comprehensive presentation of the global market for Malignant Mesothelioma Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Malignant Mesothelioma Therapeutic.
The Malignant Mesothelioma Therapeutic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Malignant Mesothelioma Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Malignant Mesothelioma Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Malignant Mesothelioma Therapeutic Market Report

Report Metric Details
Report Name Malignant Mesothelioma Therapeutic Market
Accounted market size in year US$ 377 million
Forecasted market size in 2031 US$ 602 million
CAGR 7.0%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, Pfizer, Roche, Merck, Ono Pharmaceutical, Mylan, Fresenius Kabi, Sun Pharmaceuticals, Eagle Pharmaceuticals, Qilu Pharma, Sichuan Huiyu Pharma, Nippon Kayaku, Jiangsu Haosen, Amgen
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Malignant Mesothelioma Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Malignant Mesothelioma Therapeutic Market growing?

Ans: The Malignant Mesothelioma Therapeutic Market witnessing a CAGR of 7.0% during the forecast period 2025-2031.

What is the Malignant Mesothelioma Therapeutic Market size in 2031?

Ans: The Malignant Mesothelioma Therapeutic Market size in 2031 will be US$ 602 million.

Who are the main players in the Malignant Mesothelioma Therapeutic Market report?

Ans: The main players in the Malignant Mesothelioma Therapeutic Market are Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, Pfizer, Roche, Merck, Ono Pharmaceutical, Mylan, Fresenius Kabi, Sun Pharmaceuticals, Eagle Pharmaceuticals, Qilu Pharma, Sichuan Huiyu Pharma, Nippon Kayaku, Jiangsu Haosen, Amgen

What are the Application segmentation covered in the Malignant Mesothelioma Therapeutic Market report?

Ans: The Applications covered in the Malignant Mesothelioma Therapeutic Market report are Pleural Mesothelioma, Peritoneal Mesothelioma, Others

What are the Type segmentation covered in the Malignant Mesothelioma Therapeutic Market report?

Ans: The Types covered in the Malignant Mesothelioma Therapeutic Market report are Pemetrexed, Cisplatin, Immunotherapy Agents, Others

Recommended Reports

Cancer Therapeutics

Lung and Chest Cancer

Advanced Cancer Treatments

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Pemetrexed
1.2.3 Cisplatin
1.2.4 Immunotherapy Agents
1.2.5 Others
1.3 Market by Application
1.3.1 Global Malignant Mesothelioma Therapeutic Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pleural Mesothelioma
1.3.3 Peritoneal Mesothelioma
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Malignant Mesothelioma Therapeutic Market Perspective (2020-2031)
2.2 Global Malignant Mesothelioma Therapeutic Growth Trends by Region
2.2.1 Global Malignant Mesothelioma Therapeutic Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Malignant Mesothelioma Therapeutic Historic Market Size by Region (2020-2025)
2.2.3 Malignant Mesothelioma Therapeutic Forecasted Market Size by Region (2026-2031)
2.3 Malignant Mesothelioma Therapeutic Market Dynamics
2.3.1 Malignant Mesothelioma Therapeutic Industry Trends
2.3.2 Malignant Mesothelioma Therapeutic Market Drivers
2.3.3 Malignant Mesothelioma Therapeutic Market Challenges
2.3.4 Malignant Mesothelioma Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Malignant Mesothelioma Therapeutic Players by Revenue
3.1.1 Global Top Malignant Mesothelioma Therapeutic Players by Revenue (2020-2025)
3.1.2 Global Malignant Mesothelioma Therapeutic Revenue Market Share by Players (2020-2025)
3.2 Global Top Malignant Mesothelioma Therapeutic Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Malignant Mesothelioma Therapeutic Revenue
3.4 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio
3.4.1 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Malignant Mesothelioma Therapeutic Revenue in 2024
3.5 Global Key Players of Malignant Mesothelioma Therapeutic Head office and Area Served
3.6 Global Key Players of Malignant Mesothelioma Therapeutic, Product and Application
3.7 Global Key Players of Malignant Mesothelioma Therapeutic, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Malignant Mesothelioma Therapeutic Breakdown Data by Type
4.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Type (2020-2025)
4.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Type (2026-2031)
5 Malignant Mesothelioma Therapeutic Breakdown Data by Application
5.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Application (2020-2025)
5.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Malignant Mesothelioma Therapeutic Market Size (2020-2031)
6.2 North America Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Malignant Mesothelioma Therapeutic Market Size by Country (2020-2025)
6.4 North America Malignant Mesothelioma Therapeutic Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Malignant Mesothelioma Therapeutic Market Size (2020-2031)
7.2 Europe Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2020-2025)
7.4 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size (2020-2031)
8.2 Asia-Pacific Malignant Mesothelioma Therapeutic Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2020-2025)
8.4 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Malignant Mesothelioma Therapeutic Market Size (2020-2031)
9.2 Latin America Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2020-2025)
9.4 Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size (2020-2031)
10.2 Middle East & Africa Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2020-2025)
10.4 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Details
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Malignant Mesothelioma Therapeutic Introduction
11.1.4 Eli Lilly Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.1.5 Eli Lilly Recent Development
11.2 Teva
11.2.1 Teva Company Details
11.2.2 Teva Business Overview
11.2.3 Teva Malignant Mesothelioma Therapeutic Introduction
11.2.4 Teva Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.2.5 Teva Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Malignant Mesothelioma Therapeutic Introduction
11.3.4 Sanofi Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.3.5 Sanofi Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Introduction
11.4.4 Bristol-Myers Squibb Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Malignant Mesothelioma Therapeutic Introduction
11.5.4 Pfizer Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.5.5 Pfizer Recent Development
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche Malignant Mesothelioma Therapeutic Introduction
11.6.4 Roche Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.6.5 Roche Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Malignant Mesothelioma Therapeutic Introduction
11.7.4 Merck Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.7.5 Merck Recent Development
11.8 Ono Pharmaceutical
11.8.1 Ono Pharmaceutical Company Details
11.8.2 Ono Pharmaceutical Business Overview
11.8.3 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Introduction
11.8.4 Ono Pharmaceutical Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.8.5 Ono Pharmaceutical Recent Development
11.9 Mylan
11.9.1 Mylan Company Details
11.9.2 Mylan Business Overview
11.9.3 Mylan Malignant Mesothelioma Therapeutic Introduction
11.9.4 Mylan Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.9.5 Mylan Recent Development
11.10 Fresenius Kabi
11.10.1 Fresenius Kabi Company Details
11.10.2 Fresenius Kabi Business Overview
11.10.3 Fresenius Kabi Malignant Mesothelioma Therapeutic Introduction
11.10.4 Fresenius Kabi Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.10.5 Fresenius Kabi Recent Development
11.11 Sun Pharmaceuticals
11.11.1 Sun Pharmaceuticals Company Details
11.11.2 Sun Pharmaceuticals Business Overview
11.11.3 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Introduction
11.11.4 Sun Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.11.5 Sun Pharmaceuticals Recent Development
11.12 Eagle Pharmaceuticals
11.12.1 Eagle Pharmaceuticals Company Details
11.12.2 Eagle Pharmaceuticals Business Overview
11.12.3 Eagle Pharmaceuticals Malignant Mesothelioma Therapeutic Introduction
11.12.4 Eagle Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.12.5 Eagle Pharmaceuticals Recent Development
11.13 Qilu Pharma
11.13.1 Qilu Pharma Company Details
11.13.2 Qilu Pharma Business Overview
11.13.3 Qilu Pharma Malignant Mesothelioma Therapeutic Introduction
11.13.4 Qilu Pharma Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.13.5 Qilu Pharma Recent Development
11.14 Sichuan Huiyu Pharma
11.14.1 Sichuan Huiyu Pharma Company Details
11.14.2 Sichuan Huiyu Pharma Business Overview
11.14.3 Sichuan Huiyu Pharma Malignant Mesothelioma Therapeutic Introduction
11.14.4 Sichuan Huiyu Pharma Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.14.5 Sichuan Huiyu Pharma Recent Development
11.15 Nippon Kayaku
11.15.1 Nippon Kayaku Company Details
11.15.2 Nippon Kayaku Business Overview
11.15.3 Nippon Kayaku Malignant Mesothelioma Therapeutic Introduction
11.15.4 Nippon Kayaku Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.15.5 Nippon Kayaku Recent Development
11.16 Jiangsu Haosen
11.16.1 Jiangsu Haosen Company Details
11.16.2 Jiangsu Haosen Business Overview
11.16.3 Jiangsu Haosen Malignant Mesothelioma Therapeutic Introduction
11.16.4 Jiangsu Haosen Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.16.5 Jiangsu Haosen Recent Development
11.17 Amgen
11.17.1 Amgen Company Details
11.17.2 Amgen Business Overview
11.17.3 Amgen Malignant Mesothelioma Therapeutic Introduction
11.17.4 Amgen Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025)
11.17.5 Amgen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Eli Lilly
TEVA
Sanofi
Bristol–Myers Squibb
Pfizer Inc
Roche
Merck
Ono Pharmaceutical
Mylan NV
Fresenius Kabi
Sun Pharmaceuticals
Eagle Pharmaceuticals
Qilu Pharma
Sichuan Huiyu Pharma
Nippon Kayaku
Amgen Inc
Jiangsu Haosen
List of Tables
 Table 1. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Pemetrexed
 Table 3. Key Players of Cisplatin
 Table 4. Key Players of Immunotherapy Agents
 Table 5. Key Players of Others
 Table 6. Global Malignant Mesothelioma Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Malignant Mesothelioma Therapeutic Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Malignant Mesothelioma Therapeutic Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global Malignant Mesothelioma Therapeutic Market Share by Region (2020-2025)
 Table 10. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global Malignant Mesothelioma Therapeutic Market Share by Region (2026-2031)
 Table 12. Malignant Mesothelioma Therapeutic Market Trends
 Table 13. Malignant Mesothelioma Therapeutic Market Drivers
 Table 14. Malignant Mesothelioma Therapeutic Market Challenges
 Table 15. Malignant Mesothelioma Therapeutic Market Restraints
 Table 16. Global Malignant Mesothelioma Therapeutic Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global Malignant Mesothelioma Therapeutic Market Share by Players (2020-2025)
 Table 18. Global Top Malignant Mesothelioma Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Mesothelioma Therapeutic as of 2024)
 Table 19. Ranking of Global Top Malignant Mesothelioma Therapeutic Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by Malignant Mesothelioma Therapeutic Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of Malignant Mesothelioma Therapeutic, Headquarters and Area Served
 Table 22. Global Key Players of Malignant Mesothelioma Therapeutic, Product and Application
 Table 23. Global Key Players of Malignant Mesothelioma Therapeutic, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Malignant Mesothelioma Therapeutic Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2020-2025)
 Table 27. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2026-2031)
 Table 29. Global Malignant Mesothelioma Therapeutic Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2020-2025)
 Table 31. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2026-2031)
 Table 33. North America Malignant Mesothelioma Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America Malignant Mesothelioma Therapeutic Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America Malignant Mesothelioma Therapeutic Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe Malignant Mesothelioma Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe Malignant Mesothelioma Therapeutic Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe Malignant Mesothelioma Therapeutic Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Malignant Mesothelioma Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Eli Lilly Company Details
 Table 49. Eli Lilly Business Overview
 Table 50. Eli Lilly Malignant Mesothelioma Therapeutic Product
 Table 51. Eli Lilly Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 52. Eli Lilly Recent Development
 Table 53. Teva Company Details
 Table 54. Teva Business Overview
 Table 55. Teva Malignant Mesothelioma Therapeutic Product
 Table 56. Teva Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 57. Teva Recent Development
 Table 58. Sanofi Company Details
 Table 59. Sanofi Business Overview
 Table 60. Sanofi Malignant Mesothelioma Therapeutic Product
 Table 61. Sanofi Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 62. Sanofi Recent Development
 Table 63. Bristol-Myers Squibb Company Details
 Table 64. Bristol-Myers Squibb Business Overview
 Table 65. Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Product
 Table 66. Bristol-Myers Squibb Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 67. Bristol-Myers Squibb Recent Development
 Table 68. Pfizer Company Details
 Table 69. Pfizer Business Overview
 Table 70. Pfizer Malignant Mesothelioma Therapeutic Product
 Table 71. Pfizer Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 72. Pfizer Recent Development
 Table 73. Roche Company Details
 Table 74. Roche Business Overview
 Table 75. Roche Malignant Mesothelioma Therapeutic Product
 Table 76. Roche Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 77. Roche Recent Development
 Table 78. Merck Company Details
 Table 79. Merck Business Overview
 Table 80. Merck Malignant Mesothelioma Therapeutic Product
 Table 81. Merck Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 82. Merck Recent Development
 Table 83. Ono Pharmaceutical Company Details
 Table 84. Ono Pharmaceutical Business Overview
 Table 85. Ono Pharmaceutical Malignant Mesothelioma Therapeutic Product
 Table 86. Ono Pharmaceutical Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 87. Ono Pharmaceutical Recent Development
 Table 88. Mylan Company Details
 Table 89. Mylan Business Overview
 Table 90. Mylan Malignant Mesothelioma Therapeutic Product
 Table 91. Mylan Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 92. Mylan Recent Development
 Table 93. Fresenius Kabi Company Details
 Table 94. Fresenius Kabi Business Overview
 Table 95. Fresenius Kabi Malignant Mesothelioma Therapeutic Product
 Table 96. Fresenius Kabi Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 97. Fresenius Kabi Recent Development
 Table 98. Sun Pharmaceuticals Company Details
 Table 99. Sun Pharmaceuticals Business Overview
 Table 100. Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Product
 Table 101. Sun Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 102. Sun Pharmaceuticals Recent Development
 Table 103. Eagle Pharmaceuticals Company Details
 Table 104. Eagle Pharmaceuticals Business Overview
 Table 105. Eagle Pharmaceuticals Malignant Mesothelioma Therapeutic Product
 Table 106. Eagle Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 107. Eagle Pharmaceuticals Recent Development
 Table 108. Qilu Pharma Company Details
 Table 109. Qilu Pharma Business Overview
 Table 110. Qilu Pharma Malignant Mesothelioma Therapeutic Product
 Table 111. Qilu Pharma Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 112. Qilu Pharma Recent Development
 Table 113. Sichuan Huiyu Pharma Company Details
 Table 114. Sichuan Huiyu Pharma Business Overview
 Table 115. Sichuan Huiyu Pharma Malignant Mesothelioma Therapeutic Product
 Table 116. Sichuan Huiyu Pharma Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 117. Sichuan Huiyu Pharma Recent Development
 Table 118. Nippon Kayaku Company Details
 Table 119. Nippon Kayaku Business Overview
 Table 120. Nippon Kayaku Malignant Mesothelioma Therapeutic Product
 Table 121. Nippon Kayaku Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 122. Nippon Kayaku Recent Development
 Table 123. Jiangsu Haosen Company Details
 Table 124. Jiangsu Haosen Business Overview
 Table 125. Jiangsu Haosen Malignant Mesothelioma Therapeutic Product
 Table 126. Jiangsu Haosen Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 127. Jiangsu Haosen Recent Development
 Table 128. Amgen Company Details
 Table 129. Amgen Business Overview
 Table 130. Amgen Malignant Mesothelioma Therapeutic Product
 Table 131. Amgen Revenue in Malignant Mesothelioma Therapeutic Business (2020-2025) & (US$ Million)
 Table 132. Amgen Recent Development
 Table 133. Research Programs/Design for This Report
 Table 134. Key Data Information from Secondary Sources
 Table 135. Key Data Information from Primary Sources
 Table 136. Authors List of This Report


List of Figures
 Figure 1. Malignant Mesothelioma Therapeutic Picture
 Figure 2. Global Malignant Mesothelioma Therapeutic Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Malignant Mesothelioma Therapeutic Market Share by Type: 2024 VS 2031
 Figure 4. Pemetrexed Features
 Figure 5. Cisplatin Features
 Figure 6. Immunotherapy Agents Features
 Figure 7. Others Features
 Figure 8. Global Malignant Mesothelioma Therapeutic Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global Malignant Mesothelioma Therapeutic Market Share by Application: 2024 VS 2031
 Figure 10. Pleural Mesothelioma Case Studies
 Figure 11. Peritoneal Mesothelioma Case Studies
 Figure 12. Others Case Studies
 Figure 13. Malignant Mesothelioma Therapeutic Report Years Considered
 Figure 14. Global Malignant Mesothelioma Therapeutic Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Malignant Mesothelioma Therapeutic Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Malignant Mesothelioma Therapeutic Market Share by Region: 2024 VS 2031
 Figure 17. Global Malignant Mesothelioma Therapeutic Market Share by Players in 2024
 Figure 18. Global Malignant Mesothelioma Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 19. The Top 10 and 5 Players Market Share by Malignant Mesothelioma Therapeutic Revenue in 2024
 Figure 20. North America Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Malignant Mesothelioma Therapeutic Market Share by Country (2020-2031)
 Figure 22. United States Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Malignant Mesothelioma Therapeutic Market Share by Country (2020-2031)
 Figure 26. Germany Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Ireland Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Malignant Mesothelioma Therapeutic Market Share by Region (2020-2031)
 Figure 34. China Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia & New Zealand Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Malignant Mesothelioma Therapeutic Market Share by Country (2020-2031)
 Figure 42. Mexico Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Malignant Mesothelioma Therapeutic Market Share by Country (2020-2031)
 Figure 46. Israel Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Malignant Mesothelioma Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Eli Lilly Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 50. Teva Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 51. Sanofi Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 53. Pfizer Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 54. Roche Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 55. Merck Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 56. Ono Pharmaceutical Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 57. Mylan Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 58. Fresenius Kabi Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 59. Sun Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 60. Eagle Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 61. Qilu Pharma Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 62. Sichuan Huiyu Pharma Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 63. Nippon Kayaku Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 64. Jiangsu Haosen Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 65. Amgen Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2020-2025)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

Global Malignant Pleural Mesothelioma Treatment Market Insights Forecast to 2030
Global Uterine Sarcoma Treatment Market Insights Forecast to 2030
Global Rectal Cancer Therapeutics Market Insights Forecast to 2030
Global Malignant Ascites Treatment Market Insights Forecast to 2030
Global Adult Malignant Glioma Therapeutics Market Insights Forecast to 2030
Global Malignant Glioma Therapeutics Market Research Report 2024
Global Uterine Cancer Therapies and Diagnostic Market Insights Forecast to 2030
Global Asbestosis Treatment Drugs Market Research Report 2025
Global Solid Tumor Cancer Treatment Market Insights Forecast to 2030
Global Cell Separation and Characterization in Solid Tumors Market Insights Forecast to 2030
Global Fallopian Tube Cancer Therapeutics Market Insights Forecast to 2030
Global Ovarian Cancer Market Research Report 2024
Global Drugs for Oncology Market Insights Forecast to 2030
Hematologic Malignancies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Prostate Cancer Market Insights Forecast to 2030
Global Oncology Drugs Market Insights Forecast to 2030
Global Solid Tumor Therapeutics Market Research Report 2024
Global Oncology Therapeutic Drug Market Research Report 2024
Adult Malignant Glioma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Metastatic Bones Cancer Market Insights Forecast to 2030

RELATED REPORTS

Global Fixation Device for Radiotherapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4H16852
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Group A Streptococcus for Injection Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-37K16619
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Boron Neutron Capture Therapy System Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-30U16301
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Radioactive Glass Microsphere Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-2G16953
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions